• Near Patient Molecular Testing in Sepsis

  NCT05469048

  CompletedObservationalUpdated Oct 2, 2024
• Fast Assay for Pathogen Identification and Characterization

  NCT03841162

  CompletedObservationalUpdated Apr 29, 2020
• C-reactive Protein Information and Blood Cultures for Emergency Department Patients With Sepsis

  NCT03714841

  Unknown statusInterventionalNot ApplicableUpdated Nov 20, 2020
• Evaluation of Droplet Digital PCR Rapid Detection Method and Precise Diagnosis and Treatment for Suspected Sepsis

  NCT05190861

  CompletedInterventionalNot ApplicableUpdated Jul 11, 2025
• Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT)

  NCT02743585

  Unknown statusInterventionalNot ApplicableUpdated Sep 10, 2019
• Sepsis Multiomic Analysis & Risk sTratification in China

  NCT07599644

  RecruitingObservationalUpdated Jul 10, 2026

ClinicalTrials.gov ID

NCT07580001

Lead Sponsor

Shanghai 10th People's HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

396Estimated

Last Update Posted

May 12, 2026Actual

Start Date

Jul 2026Estimated

Primary Completion Date

Dec 2028Estimated

Completion Date

Dec 2028Estimated

Official Title

A Multicenter Prospective Study Evaluating the Diagnostic Performance and Impact on Clinical Outcomes of the NuRapid-CRISPR Pathogen Profile Assay in ICU Patients With Sepsis

Brief Summary

This study is a prospective, multicenter, integrated trial designed to evaluate, from the perspectives of diagnostic performance and clinical utility, whether a diagnostic and treatment strategy based on the NuRapid-CRISPR rapid pathogen detection technology can reduce the 28-day all-cause mortality rate in patients with sepsis or septic shock in the ICU, compared to traditional pathogen culture.

The study consists of two parts:

1. Diagnostic Accuracy Study: For all enrolled sepsis patients, microbiological specimens will undergo concurrent blinded testing, with NuRapid-CRISPR serving as the test of interest and traditional pathogen culture as the reference standard. A prospective comparison will evaluate differences between the two methods in key metrics such as pathogen detection rate, sensitivity, specificity, and turnaround time.
2. Clinical Utility Cohort Study: All patients will undergo NuRapid-CRISPR testing as part of routine clinical care. Based on whether the rapid results are adopted clinically to guide early antimicrobial therapy decisions, the cohort will naturally form an exposure group (early treatment adjustments based on NuRapid-CRISPR results) and a control group (treatment primarily based on traditional culture results or empirical therapy). The study will prospectively compare the two groups in terms of the time to optimize antimicrobial therapy, coverage of the initial treatment spectrum, and infection-related clinical outcomes.

• Sepsis

• NuRapid-CRISPR Rapid Pathogen Detection Technology
• Traditional pathogen culture

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age ≥ 18 years, length of stay in the ICU ≤ 24 hours;
• Meets the Sepsis-3.0 diagnostic criteria (an increase in SOFA score of ≥2 points from baseline, and evidence of infection);
• Clinically suspected sepsis or septic shock; the pathogen is unknown; the clinical plan is to collect sterile or suitable specimens, such as blood, respiratory specimens, cerebrospinal fluid, and ascites, for microbiological testing;
• Expected ICU stay of ≥48 hours and ability to complete at least 28 days of clinical follow-up;
• A written informed consent form signed by the patient or their legally authorized representative;

Exclusion Criteria:

• At the time of admission, the patient had already received a definitive pathogen diagnosis (based on microbiological culture, reliable molecular testing, or serological evidence), and targeted antimicrobial therapy against that pathogen had been initiated for more than 48 hours;
• Vital signs are extremely unstable; death is expected within 24 hours;
• Patients with severe primary immunodeficiency (e.g., AIDS, active hematologic malignancies, post-transplantation of solid organs or hematopoietic stem cells, or long-term use of high-dose glucocorticoids [prednisone ≥ 20 mg/day or equivalent dose for more than 4 weeks] or other potent immunosuppressants);
• Women who are pregnant or breastfeeding;
• The patient or their authorized representative has expressly refused to undergo any pathogen testing;
• It is not possible to obtain a suitable specimen for testing due to anatomical, physiological, or technical reasons;
• The patient is currently participating in another interventional clinical trial that may interfere with the assessment of the primary outcome of this study;
• The patient or their authorized representative has declined to participate in this study;

Primary Purpose

Diagnostic

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Shanghai 10th People's HospitalOTHER

Collaborators

Shanghai Tongji Hospital, Tongji University School of MedicineOTHER

Yangpu District Central Hospital Affiliated to Tongji UniversityOTHER

Dongfang Hospital Affiliated to Tongji UniversityOTHER

alexzhufeng@tongji.edu.cn+86 18801780080

Joysb1969@sina.com+86 18918288036